Apitegromab for Muscle Growth - Quick Reference Sheet
evipedia.ai
← Back

Apitegromab for Muscle Growth

Created on 09/13/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Apitegromab blocks a natural brake on muscle growth. Approved only for a rare inherited muscle-wasting disease, it modestly improved movement there. In adults losing weight, it preserved much of the muscle otherwise shed, an advantage that faded within two months of stopping. Strength did not improve. A bone-fracture warning applies, and all evidence is manufacturer-funded. (Full Review)

Protocol

Standard regimen
10 mg/kg intravenous infusion every 4 weeks
Indefinitely. The approved dose and the dose used in the weight-loss trial.
Lean-mass-preservation regimen
10 mg/kg every 4 weeks alongside tirzepatide titrated to 15 mg weekly
This use is investigational, not approved.
Higher-dose alternative
20 mg/kg every 4 weeks
Tested in the phase 2 and phase 3 programmes. It performed no better and is not approved.
Time to effect
Motor function
12 months
Motor-function gains were measured at 12 months.
Lean mass
24 weeks
Lean-mass separation was measured at 24 weeks.
Target engagement
Week 16
Begins with the first dose; drug and marker levels plateau near week 16.

Benefits

Contraindications
  • Established osteoporosis (bone mineral density T-score at or below -2.5) or a prior fragility fracture
  • Prior hypersensitivity reaction to apitegromab or to another monoclonal antibody
  • Pregnant women, and women planning pregnancy within five months of a dose
  • Breastfeeding women
  • Children under 2 years
  • Competitive athletes subject to the World Anti-Doping Agency code
    •
Key Interactions
  • Systemic corticosteroids (prednisone, dexamethasone, methylprednisolone): Caution
  • Aromatase inhibitors and androgen-deprivation therapy (anastrozole, letrozole, leuprolide): Caution
  • Over-the-counter proton pump inhibitors (omeprazole, esomeprazole) and aluminium-containing antacids: Caution with prolonged use
  • Incretin therapies (tirzepatide, semaglutide, liraglutide): Monitor
  • Survival motor neuron-targeted drugs (nusinersen, risdiplam): Monitor
  • Muscle-anabolic supplements (creatine monohydrate, HMB, leucine-rich protein): Additive, not adverse
  • Calcium and vitamin D supplements: Additive in the protective direction
  • Resistance training as a co-intervention: Potentiating
  • Other over-the-counter medicines (ibuprofen, naproxen, paracetamol, antihistamines): No interaction identified
  • Live attenuated vaccines: No interaction identified
    •

Risk & Side Effects

  • High: Headache, fatigue and other non-specific adverse events
    •
  • Medium: Bone fracture; hypersensitivity reactions
    •
  • Low: Anti-drug antibody formation; creatine kinase elevation with heavy training
  • Speculative: Tendon and connective-tissue mismatch; impaired glucose control with prolonged blockade; effects on cardiac and smooth muscle; harm to reproductive function and the developing fetus

Monitoring

Marker Target Why
Appendicular lean mass index by DEXA Above 7.0 kg/m² in men, 5.5 kg/m² in women The direct readout of the intended effect
Bone mineral density T-score Above -1.0 Tracks the labelled fracture risk
Serum latent myostatin Above baseline and plateaued by week 16 Confirms the dose is engaging its target
25-hydroxyvitamin D 40-60 ng/mL Substrate for the bone response to new muscle load
Creatine kinase 60-200 U/L, or stable against personal baseline Detects muscle damage from rapid training escalation
Grip strength Above 35 kg in men, 20 kg in women Tests whether added tissue buys function
Glycated haemoglobin (HbA1c) 4.8-5.4% Watches the speculative glucose signal seen in animals
Anti-drug antibody titre Negative, or transient and low Flags an immune reaction against the drug and potential loss of effect

Cadence: Safety chemistry and creatine kinase at 4 and 12 weeks; latent myostatin at 16 weeks; body composition and strength at 24 weeks; then body composition, strength and safety chemistry every 6 months, with bone densitometry every 12 months and immediately after any fracture.

Qualitative Assessment

  • Ease of everyday tasks that load muscle — stairs, rising from a chair, carrying shopping
  • Perceived recovery time between resistance sessions
  • Fatigue during and after the week following an infusion
  • Confidence and steadiness in movement, including any near-falls
  • Any new bone or joint pain, which precedes some stress fractures
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.